GT Biopharma shareholders vote to reduce authorized common stock from 750M to 250M shares

GT Biopharma, Inc.

Special meeting held Oct 10, 2022; 17,442,945 of 31,092,498 shares represented (56.1%).
Proposal to ratify amendment reducing authorized common stock from 750M to 250M shares passed.
Vote: 17,201,108 For, 227,621 Against, 14,216 Abstain.
The amendment was previously proposed at the 2022 Annual Meeting as Proposal No. 4.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.